Esophageal Cancer Clinical Trial
Official title:
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial
In this study, non-operable esophagogastric adenocarcinoma cancer patients or non-operable
biliary cancer patients whose cancer progressed/spread/got worse after first line treatment
will be treated with or without immunotherapy and chemotherapy. This study will take place in
several countries across Europe. One hundred twenty-three (123) patients will be invited to
participate in this study
Biliary tract cancer (BTC), is a form of cancer that start in your bile ducts, a series of
tubes that runs from the liver to the small intestines. It is not know yet the exact cause of
BTC. For patients who have advanced or metastatic BTC (where surgery is not possible),
chemotherapy is the first option for treatment. Chemotherapy with cisplatin and gemcitabine
(CisGem) is the current standard of care.
Esophagogastric cancer (EGC) is cancer that occurs in the esophagus, a long hollow tube that
runs from your throat to your stomach. The accumulating abnormal cells form a tumor in the
esophagus that can grow to invade nearby structures and spread to other parts of the body.
It's thought that chronic irritation of your esophagus may contribute to the changes that
cause esophageal cancer.
The purpose of this study is to look at the risks and benefits of combining DKN-01 and
atezolizumab (humanized monoclonal antibody) with or without paclitaxel (chemotherapy).
Immune therapy boosts the body's natural defenses to fight cancer. It uses specific products
made either by participants' body or in a laboratory to improve, target or restore immune
system function and control or stop cancer. Atezolizumab is such an "immunotherapy" drug.
DKN-01 is another new type of drug (humanized monoclonal antibody) in development as
anticancer agent. Paclitaxel is a commonly-used chemotherapy drug of the class of taxanes
used to treat a number of cancer types, it stimulates the cell to die or to stop the cell
from dividing into two new cells.The idea behind combining these drugs is linked to targeting
the immune system to attack the tumor. Combining immune and chemotherapy has already
demonstrated clinical activity in relapsed (return of the disease)/refractory (not responding
to treatment) esophagogastric cancer patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
| Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
| Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
| Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
| Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
| Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
| Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
| Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
| Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
| Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
| Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |